Ireland: The EIIS: The Shining Star Amongst A Sea Of Faded Tax Reliefs

Last Updated: 11 April 2018
Article by Shane O'Donovan

In this article, Shane O'Donovan ACA, AITI, Tax Manager with PKF O'Connor, Leddy & Holmes, talks about how you can obtain tax relief through the EIIS.

Over the past eight years we've seen a number of tax reliefs abolished and the attractiveness of many other tax reliefs being limited by the high earners restriction. One of the few tax reliefs that remains is the Employment and Investment Incentive Scheme ("EIIS"). The EIIS was introduced by Finance Act 2011 and replaced the Business Expansion Scheme which had been in operation since 1984.

The EIIS is designed to encourage investment by individuals in small- and medium-sized companies. The EIIS allows an individual investor to obtain income tax relief on investments up to a maximum of €150,000 per annum in each tax year up to 2020. Individuals will qualify for EIIS relief if they subscribe for eligible shares in a qualifying company. Tax relief is given by means of a deduction from the qualifying individual's total income. Individuals will get relief as follows:

  • 30% in the year of assessment, and
  • a further 10% will be available where the company's employment levels have increased at the end of a period of three years from the investment or where evidence is provided that the company used the capital raised for expenditure on research and development.

At the end of the four-year holding period, it is possible for the investor to receive their initial investment back, provided the company has sufficient funds to repurchase the shares issued to the investor.

The benefits of the EIIS are illustrated in Table 1:

This scheme is available to the majority of small-and medium-sized trading companies, including pharmacies. Companies must use the equity raised for the purpose of carrying on relevant trading activities.

An individual cannot avail of the relief if they are connected with the qualifying company at any time during the specified period. Broadly, the specified period is a period of two years before the date on which the shares are issued and ending three years after the issue of the shares. An individual is connected to a company if the individual (or an associate of the individual) is:

  • a partner of the company; or
  • a director or employee of the company who, during the period of three years after the date on which the eligible shares were issued, receives or becomes entitled to receive any payment from the company that is not on an arm's-length basis.

In addition, an individual will be connected to a company if they own (or is entitled to acquire) more than 30% of the ordinary share capital of the company.

However, an individual will not be deemed to be connected with a company if the aggregate of all amounts subscribed for the issued share capital and loan capital of the company does not exceed €500,000.

The lack of traditional bank finance available to small- and medium-sized enterprises (SMEs) continues to be an issue in Ireland. As a result of this, many businesses are missing out on growth opportunities as they cannot source the required funding. The EIIS offers companies a mechanism for raising low cost finance which can have an immediate positive impact on both its financial and its trading position. EIIS financing offers companies a number of other positives, such as:

  • a fixed cost of finance over four years;
  • existing shareholders retain control of the business; and
  • no repayment of finance raised until the end of the four-year holding period.

The relaxation of connected party rules aggregate investments up to €500,000 provides owner managers with significant opportunity to invest funds into their own company and avail of tax relief in respect of such investments. The funds must be used by the company for trading activities such as expansion, the creation of employment or maintaining employment. The EIIS should be of particular interest to pharmacists considering expanding their existing trades or purchasing new pharmacies. The following is a worked example of how the EIIS could benefit pharmacists considering expanding.

Worked example

John and Mary are both pharmacists and jointly own Clued In Pharmacy Limited. John and Mary have identified a pharmacy which they are interested in purchasing. The cost of acquiring the pharmacy is €1m. The question arises as to how the purchase of the pharmacy should be financed. The options open to John and Mary are:

  • Borrow from a financial institution;
  • Invest funds accumulated by Clued In Pharmacy Limited;
  • Use personal funds; or
  • A combination of the above.

Given the lack of credit available to SMEs in Ireland over the last number of years, it is possible that the company may not be in a position to borrow. If it is possible for the company to borrow from a financial institution, it is likely that John and Mary and the company will have to provide significant security.

Investing all funds accumulated by Clued In Pharmacy Limited may result in cashflow concerns for the company in the short to medium term.

An alternative option would be for John and Mary to invest €150,000 each in Clued In Pharmacy Limited, which could be used by the company to purchase the pharmacy. The balance of the €1m purchase price could be funded by either borrowing from a financial institution or the use of funds accumulated by the company.

The net cost of purchasing the pharmacy in the above example would be:

By availing of the EIIS, John and Mary are able to claim tax relief of €120,000 in respect of the use of their personal funds towards the purchase of the new pharmacy. At the end of the four-year holding period, it should be possible for the company to redeem John and Mary's shares issued in respect of the €300,000 investment and return their capital.


In the early years of the EIIS, commercial awareness of the scheme was low. This is evidenced by the fact that only 352 investors shared EIIS tax relief of €4m (investments of €13.4m) in 2012 and 1,011 investors shared EIIS tax relief of €12.4m (investments of €41.5m) in 2013.

When the EIIS was introduced, it was estimated that the annual cost of the scheme to the Exchequer would be €38m (investments of €128m). Finance Act (No. 2) 2013 took steps to increase the attractiveness of the EIIS by excluding it from the high-earner restriction for a three-year period until 31 December 2016. The Department of Finance published a review of the EIIS in October 2014. This review reaffirmed the Government's commitment to the EIIS. The key point to note from these figures is that the EIIS is being underutilised.

The EIIS is perhaps the one tax relief remaining which offers individuals a mechanism for reducing their overall effective rate of Income Tax. Given that a significant number of pharmacists are owner managers, there is significant scope for pharmacists to receive EIIS tax relief up to the connected party limit of €500,000.

Originally published by IPUREVIEW April 2015.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions